uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q16.1394 | Q16 | What Small molecule therapies have been approved by the FDA to treat obstructive sleep apnea? | Armodafinil is the only Small molecule therapy approved by the FDA to treat obstructive sleep apnea. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "obstructive sleep apnea" OR LOWER(mesh_heading) = "obstructive sleep apnea") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_939005', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939024', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939043', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939062', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939081', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939100', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939119', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939138', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939157', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939176', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939195', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939214', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939233', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939252', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939271', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939290', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939309', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939328', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939347', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}, {'UUID': 'DrugTargetsIndication121923_text_939366', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Apnea, Obstructive', 'efo_term': 'obstructive sleep apnea'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.991 | Q16 | What Small molecule therapies have been approved by the FDA to treat diabetic retinopathy? | Dexamethasone is the only Small molecule therapy approved by the FDA to treat diabetic retinopathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "diabetic retinopathy" OR LOWER(mesh_heading) = "diabetic retinopathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_226333', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_226618', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_226903', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_227188', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_227473', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_227758', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_228043', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_228328', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_228613', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_228898', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_229183', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_229468', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_229753', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_230038', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_230323', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_230608', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_230893', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_231178', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_231463', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_231748', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_232033', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}, {'UUID': 'DrugTargetsIndication121923_text_232318', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1680 | Q16 | What Small molecule therapies have been approved by the FDA to treat systolic heart failure? | There are no drug Small molecule therapies approved to treat systolic heart failure. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "systolic heart failure" OR LOWER(mesh_heading) = "systolic heart failure") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.579 | Q16 | What Small molecule therapies have been approved by the FDA to treat Otitis media? | There are no drug Small molecule therapies approved to treat Otitis media. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "otitis media" OR LOWER(mesh_heading) = "otitis media") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1142 | Q16 | What Small molecule therapies have been approved by the FDA to treat hepatitis B virus infection? | There are no drug Small molecule therapies approved to treat hepatitis B virus infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hepatitis b virus infection" OR LOWER(mesh_heading) = "hepatitis b virus infection") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.542 | Q16 | What Small molecule therapies have been approved by the FDA to treat Mastocytosis? | Midostaurin is the only Small molecule therapy approved by the FDA to treat Mastocytosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mastocytosis" OR LOWER(mesh_heading) = "mastocytosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_667282', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667293', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667304', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667315', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667326', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667337', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667348', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667359', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667370', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667381', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667392', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667403', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667414', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667425', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667436', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667447', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171132', 'approvedSymbol': 'PRKCE', 'approvedName': 'protein kinase C epsilon', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667458', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171132', 'approvedSymbol': 'PRKCE', 'approvedName': 'protein kinase C epsilon', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667469', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171132', 'approvedSymbol': 'PRKCE', 'approvedName': 'protein kinase C epsilon', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667480', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000166501', 'approvedSymbol': 'PRKCB', 'approvedName': 'protein kinase C beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667491', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000166501', 'approvedSymbol': 'PRKCB', 'approvedName': 'protein kinase C beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667502', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000166501', 'approvedSymbol': 'PRKCB', 'approvedName': 'protein kinase C beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667513', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115825', 'approvedSymbol': 'PRKD3', 'approvedName': 'protein kinase D3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667524', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115825', 'approvedSymbol': 'PRKD3', 'approvedName': 'protein kinase D3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667535', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115825', 'approvedSymbol': 'PRKD3', 'approvedName': 'protein kinase D3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667546', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163558', 'approvedSymbol': 'PRKCI', 'approvedName': 'protein kinase C iota', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667557', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163558', 'approvedSymbol': 'PRKCI', 'approvedName': 'protein kinase C iota', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667568', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163558', 'approvedSymbol': 'PRKCI', 'approvedName': 'protein kinase C iota', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667579', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154229', 'approvedSymbol': 'PRKCA', 'approvedName': 'protein kinase C alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667590', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154229', 'approvedSymbol': 'PRKCA', 'approvedName': 'protein kinase C alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667601', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154229', 'approvedSymbol': 'PRKCA', 'approvedName': 'protein kinase C alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667612', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126583', 'approvedSymbol': 'PRKCG', 'approvedName': 'protein kinase C gamma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667623', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126583', 'approvedSymbol': 'PRKCG', 'approvedName': 'protein kinase C gamma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667634', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126583', 'approvedSymbol': 'PRKCG', 'approvedName': 'protein kinase C gamma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667645', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163932', 'approvedSymbol': 'PRKCD', 'approvedName': 'protein kinase C delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667656', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163932', 'approvedSymbol': 'PRKCD', 'approvedName': 'protein kinase C delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667667', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163932', 'approvedSymbol': 'PRKCD', 'approvedName': 'protein kinase C delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667678', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067606', 'approvedSymbol': 'PRKCZ', 'approvedName': 'protein kinase C zeta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667689', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067606', 'approvedSymbol': 'PRKCZ', 'approvedName': 'protein kinase C zeta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667700', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067606', 'approvedSymbol': 'PRKCZ', 'approvedName': 'protein kinase C zeta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667711', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000027075', 'approvedSymbol': 'PRKCH', 'approvedName': 'protein kinase C eta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667722', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000027075', 'approvedSymbol': 'PRKCH', 'approvedName': 'protein kinase C eta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667733', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000027075', 'approvedSymbol': 'PRKCH', 'approvedName': 'protein kinase C eta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667744', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184304', 'approvedSymbol': 'PRKD1', 'approvedName': 'protein kinase D1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667755', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184304', 'approvedSymbol': 'PRKD1', 'approvedName': 'protein kinase D1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667766', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184304', 'approvedSymbol': 'PRKD1', 'approvedName': 'protein kinase D1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667777', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065675', 'approvedSymbol': 'PRKCQ', 'approvedName': 'protein kinase C theta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667788', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065675', 'approvedSymbol': 'PRKCQ', 'approvedName': 'protein kinase C theta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667799', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065675', 'approvedSymbol': 'PRKCQ', 'approvedName': 'protein kinase C theta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis', 'efo_term': 'Mastocytosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.253 | Q16 | What Protein therapies have been approved by the FDA to treat parathyroid disease? | Velcalcetide is the only Protein therapy approved by the FDA to treat parathyroid disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "parathyroid disease" OR LOWER(mesh_heading) = "parathyroid disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1148946', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148949', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148952', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148955', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148958', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148961', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148964', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148967', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148970', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148973', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148976', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148979', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148982', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148985', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148988', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148991', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148994', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148997', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1149000', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1149003', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}, {'UUID': 'DrugTargetsIndication121923_text_1149006', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.728 | Q16 | What Small molecule therapies have been approved by the FDA to treat albuminuria? | There are no drug Small molecule therapies approved to treat albuminuria. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "albuminuria" OR LOWER(mesh_heading) = "albuminuria") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1572 | Q16 | What Small molecule therapies have been approved by the FDA to treat renal osteodystrophy? | There are no drug Small molecule therapies approved to treat renal osteodystrophy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "renal osteodystrophy" OR LOWER(mesh_heading) = "renal osteodystrophy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.531 | Q16 | What Small molecule therapies have been approved by the FDA to treat Lassa fever? | There are no drug Small molecule therapies approved to treat Lassa fever. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lassa fever" OR LOWER(mesh_heading) = "lassa fever") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1315 | Q16 | What Small molecule therapies have been approved by the FDA to treat metastasis? | There are 2 Small molecule therapy drugs that are approved to treat metastasis which are as follows: Larotrectinib Sulfate and Zoledronic Acid. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "metastasis" OR LOWER(mesh_heading) = "metastasis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_942603', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942606', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942609', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942612', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942615', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942618', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942621', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942624', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942627', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942630', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942633', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942636', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942639', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942642', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942645', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942648', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942651', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942654', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942657', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942660', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942663', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942666', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942669', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942672', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942675', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942678', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942681', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942684', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942687', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942690', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942693', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942696', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942699', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942702', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942705', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942708', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942711', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942714', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942717', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942720', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942723', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942726', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942729', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942732', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942735', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942738', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942741', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942744', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942747', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942750', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942753', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942756', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942759', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942762', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942765', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942768', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942771', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942774', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942777', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942780', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942783', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942786', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942789', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942792', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942795', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942798', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942801', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942804', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942807', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942810', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942813', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942816', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942819', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942822', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942825', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942828', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942831', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942834', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942837', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942840', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148053', 'approvedSymbol': 'NTRK2', 'approvedName': 'neurotrophic receptor tyrosine kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942843', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942846', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942849', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942852', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942855', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942858', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942861', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942864', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942867', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942870', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942873', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942876', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942879', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942882', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942885', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942888', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942891', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942894', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942897', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_942900', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140538', 'approvedSymbol': 'NTRK3', 'approvedName': 'neurotrophic receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.990 | Q16 | What Small molecule therapies have been approved by the FDA to treat diabetic polyneuropathy? | There are no drug Small molecule therapies approved to treat diabetic polyneuropathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "diabetic polyneuropathy" OR LOWER(mesh_heading) = "diabetic polyneuropathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.242 | Q16 | What Protein therapies have been approved by the FDA to treat non-alcoholic steatohepatitis? | There are no drug Protein therapies approved to treat non-alcoholic steatohepatitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "non-alcoholic steatohepatitis" OR LOWER(mesh_heading) = "non-alcoholic steatohepatitis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.877 | Q16 | What Small molecule therapies have been approved by the FDA to treat central nervous system cancer? | There are no drug Small molecule therapies approved to treat central nervous system cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "central nervous system cancer" OR LOWER(mesh_heading) = "central nervous system cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1172 | Q16 | What Small molecule therapies have been approved by the FDA to treat hypoplastic left heart syndrome? | There are no drug Small molecule therapies approved to treat hypoplastic left heart syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypoplastic left heart syndrome" OR LOWER(mesh_heading) = "hypoplastic left heart syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.911 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic granulomatous disease? | There are no drug Small molecule therapies approved to treat chronic granulomatous disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic granulomatous disease" OR LOWER(mesh_heading) = "chronic granulomatous disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1606 | Q16 | What Small molecule therapies have been approved by the FDA to treat sclerosing cholangitis? | There are no drug Small molecule therapies approved to treat sclerosing cholangitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sclerosing cholangitis" OR LOWER(mesh_heading) = "sclerosing cholangitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.698 | Q16 | What Small molecule therapies have been approved by the FDA to treat acute coronary syndrome? | Ticagrelor is the only Small molecule therapy approved by the FDA to treat acute coronary syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute coronary syndrome" OR LOWER(mesh_heading) = "acute coronary syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_920338', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920364', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920390', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920416', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920442', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920468', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920494', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920520', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920546', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920572', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920598', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920624', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920650', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920676', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920702', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920728', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920754', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920780', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920806', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920832', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920858', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920884', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920910', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920936', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920962', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_920988', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Coronary Syndrome', 'efo_term': 'acute coronary syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.437 | Q16 | What Small molecule therapies have been approved by the FDA to treat Facioscapulohumeral dystrophy? | There are no drug Small molecule therapies approved to treat Facioscapulohumeral dystrophy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "facioscapulohumeral dystrophy" OR LOWER(mesh_heading) = "facioscapulohumeral dystrophy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.72 | Q16 | What Protein therapies have been approved by the FDA to treat Waldenstrom macroglobulinemia? | There are no drug Protein therapies approved to treat Waldenstrom macroglobulinemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "waldenstrom macroglobulinemia" OR LOWER(mesh_heading) = "waldenstrom macroglobulinemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1740 | Q16 | What Small molecule therapies have been approved by the FDA to treat vaginal cancer? | There are no drug Small molecule therapies approved to treat vaginal cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "vaginal cancer" OR LOWER(mesh_heading) = "vaginal cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.261 | Q16 | What Protein therapies have been approved by the FDA to treat polycystic ovary syndrome? | There are no drug Protein therapies approved to treat polycystic ovary syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "polycystic ovary syndrome" OR LOWER(mesh_heading) = "polycystic ovary syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.52 | Q16 | What Protein therapies have been approved by the FDA to treat Mantle cell lymphoma? | There are no drug Protein therapies approved to treat Mantle cell lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mantle cell lymphoma" OR LOWER(mesh_heading) = "mantle cell lymphoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1587 | Q16 | What Small molecule therapies have been approved by the FDA to treat rheumatic disease? | There are 6 Small molecule therapy drugs that are approved to treat rheumatic disease which are as follows: Indomethacin, Celecoxib, Diclofenac, Naproxen, Ibuprofen, and Meloxicam. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "rheumatic disease" OR LOWER(mesh_heading) = "rheumatic disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828206', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_828240', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_828274', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_828308', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_828342', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_828376', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_828410', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_828444', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_828478', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_828512', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_828546', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_828580', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_832946', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_833057', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_833168', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_833279', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_833390', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_833501', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_836981', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837011', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837041', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837071', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837101', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837131', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837161', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837191', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837221', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837251', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837281', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837311', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837341', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837371', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837401', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837431', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837461', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837491', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837521', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837551', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837581', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837611', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837641', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837671', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837701', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837731', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837761', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837791', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837821', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837851', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837881', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837911', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837941', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_837971', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838001', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838031', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838338', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838379', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838420', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838461', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838502', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838543', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838584', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838625', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838666', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838707', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838748', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838789', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838830', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838871', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838912', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838953', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_838994', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839035', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839076', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839117', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839158', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839199', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839240', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839281', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839322', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839363', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839404', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839445', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839486', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839527', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839568', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839609', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839650', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839691', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839771', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839850', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_839929', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_840008', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_840087', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_840166', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_840245', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_840324', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_840403', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_840482', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_840561', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}, {'UUID': 'DrugTargetsIndication121923_text_840640', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1196 | Q16 | What Small molecule therapies have been approved by the FDA to treat inflammatory myofibroblastic tumor? | There are no drug Small molecule therapies approved to treat inflammatory myofibroblastic tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "inflammatory myofibroblastic tumor" OR LOWER(mesh_heading) = "inflammatory myofibroblastic tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.595 | Q16 | What Small molecule therapies have been approved by the FDA to treat Polycystic Kidney Disease? | Tolvaptan is the only Small molecule therapy approved by the FDA to treat Polycystic Kidney Disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "polycystic kidney disease" OR LOWER(mesh_heading) = "polycystic kidney disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_695097', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695098', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695112', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695113', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695127', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695128', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695142', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695143', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695157', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695158', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695172', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695173', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695187', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695188', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695202', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695203', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695217', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695218', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695232', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695233', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695247', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695248', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695262', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695263', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695277', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695278', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695292', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695293', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695307', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695308', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_695322', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease'}, {'UUID': 'DrugTargetsIndication121923_text_695323', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1466 | Q16 | What Small molecule therapies have been approved by the FDA to treat peripheral vascular disease? | There are no drug Small molecule therapies approved to treat peripheral vascular disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "peripheral vascular disease" OR LOWER(mesh_heading) = "peripheral vascular disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1211 | Q16 | What Small molecule therapies have been approved by the FDA to treat intestinal polyp? | There are no drug Small molecule therapies approved to treat intestinal polyp. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intestinal polyp" OR LOWER(mesh_heading) = "intestinal polyp") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.814 | Q16 | What Small molecule therapies have been approved by the FDA to treat benign prostatic hyperplasia? | Tadalafil is the only Small molecule therapy approved by the FDA to treat benign prostatic hyperplasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "benign prostatic hyperplasia" OR LOWER(mesh_heading) = "benign prostatic hyperplasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094100', 'drugName': 'Tadalafil', 'tradeNames_list': "['Adcirca', 'Cialis', 'Tadliq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Hyperplasia', 'efo_term': 'benign prostatic hyperplasia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.674 | Q16 | What Small molecule therapies have been approved by the FDA to treat Venous thrombosis? | There are 2 Small molecule therapy drugs that are approved to treat Venous thrombosis which are as follows: Rivaroxaban and Apixaban. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "venous thrombosis" OR LOWER(mesh_heading) = "venous thrombosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_708680', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708683', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708715', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708718', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708750', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708753', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708785', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708788', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708820', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708823', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708855', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708858', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708890', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708893', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708925', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708928', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708960', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708963', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708995', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708998', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709030', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709033', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709065', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709068', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709100', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709103', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709135', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709138', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709170', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709173', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709205', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709208', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709240', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709243', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709275', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709278', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709310', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709313', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709345', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709348', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709380', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709383', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709415', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709418', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709450', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709453', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709485', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709488', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709520', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709523', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709555', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709558', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709590', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709593', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709625', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709628', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709660', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709663', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709695', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709698', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709730', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709733', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709765', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709768', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709800', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709803', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709835', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709838', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709870', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709873', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709905', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709908', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709940', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709943', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709975', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709978', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710010', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710013', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710045', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710048', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710080', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710083', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710115', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710118', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710150', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710153', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710185', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710188', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710220', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710223', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710255', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710258', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710290', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710293', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710301', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710308', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710315', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710322', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710329', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710336', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.617 | Q16 | What Small molecule therapies have been approved by the FDA to treat Rigidity? | Baclofen is the only Small molecule therapy approved by the FDA to treat Rigidity. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "rigidity" OR LOWER(mesh_heading) = "rigidity") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193119', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity'}, {'UUID': 'DrugTargetsIndication121923_text_1193144', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity'}, {'UUID': 'DrugTargetsIndication121923_text_1193169', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity'}, {'UUID': 'DrugTargetsIndication121923_text_1193194', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity'}, {'UUID': 'DrugTargetsIndication121923_text_1193219', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity'}, {'UUID': 'DrugTargetsIndication121923_text_1193244', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity'}, {'UUID': 'DrugTargetsIndication121923_text_1193269', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity'}, {'UUID': 'DrugTargetsIndication121923_text_1193294', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity'}, {'UUID': 'DrugTargetsIndication121923_text_1193319', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity'}, {'UUID': 'DrugTargetsIndication121923_text_1193344', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1247 | Q16 | What Small molecule therapies have been approved by the FDA to treat lentigo? | Tazarotene is the only Small molecule therapy approved by the FDA to treat lentigo. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lentigo" OR LOWER(mesh_heading) = "lentigo") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055462', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000172819', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lentigo', 'efo_term': 'lentigo'}, {'UUID': 'DrugTargetsIndication121923_text_1055470', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000172819', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lentigo', 'efo_term': 'lentigo'}, {'UUID': 'DrugTargetsIndication121923_text_1055478', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000172819', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lentigo', 'efo_term': 'lentigo'}, {'UUID': 'DrugTargetsIndication121923_text_1055486', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000172819', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lentigo', 'efo_term': 'lentigo'}, {'UUID': 'DrugTargetsIndication121923_text_1055494', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000077092', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lentigo', 'efo_term': 'lentigo'}, {'UUID': 'DrugTargetsIndication121923_text_1055502', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000077092', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lentigo', 'efo_term': 'lentigo'}, {'UUID': 'DrugTargetsIndication121923_text_1055510', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000077092', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lentigo', 'efo_term': 'lentigo'}, {'UUID': 'DrugTargetsIndication121923_text_1055518', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000077092', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lentigo', 'efo_term': 'lentigo'}, {'UUID': 'DrugTargetsIndication121923_text_1055526', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000131759', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lentigo', 'efo_term': 'lentigo'}, {'UUID': 'DrugTargetsIndication121923_text_1055534', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000131759', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lentigo', 'efo_term': 'lentigo'}, {'UUID': 'DrugTargetsIndication121923_text_1055542', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000131759', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lentigo', 'efo_term': 'lentigo'}, {'UUID': 'DrugTargetsIndication121923_text_1055550', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000131759', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lentigo', 'efo_term': 'lentigo'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1127 | Q16 | What Small molecule therapies have been approved by the FDA to treat heart disease? | There are no drug Small molecule therapies approved to treat heart disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "heart disease" OR LOWER(mesh_heading) = "heart disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.426 | Q16 | What Small molecule therapies have been approved by the FDA to treat Eosinophilia? | There are no drug Small molecule therapies approved to treat Eosinophilia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "eosinophilia" OR LOWER(mesh_heading) = "eosinophilia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.454 | Q16 | What Small molecule therapies have been approved by the FDA to treat Genetic hypopigmentation of the skin? | Tazarotene is the only Small molecule therapy approved by the FDA to treat Genetic hypopigmentation of the skin. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "genetic hypopigmentation of the skin" OR LOWER(mesh_heading) = "genetic hypopigmentation of the skin") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055463', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000172819', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin'}, {'UUID': 'DrugTargetsIndication121923_text_1055471', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000172819', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin'}, {'UUID': 'DrugTargetsIndication121923_text_1055479', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000172819', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin'}, {'UUID': 'DrugTargetsIndication121923_text_1055487', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000172819', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin'}, {'UUID': 'DrugTargetsIndication121923_text_1055495', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000077092', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin'}, {'UUID': 'DrugTargetsIndication121923_text_1055503', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000077092', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin'}, {'UUID': 'DrugTargetsIndication121923_text_1055511', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000077092', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin'}, {'UUID': 'DrugTargetsIndication121923_text_1055519', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000077092', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin'}, {'UUID': 'DrugTargetsIndication121923_text_1055527', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000131759', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin'}, {'UUID': 'DrugTargetsIndication121923_text_1055535', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000131759', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin'}, {'UUID': 'DrugTargetsIndication121923_text_1055543', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000131759', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin'}, {'UUID': 'DrugTargetsIndication121923_text_1055551', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000131759', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypopigmentation', 'efo_term': 'Genetic hypopigmentation of the skin'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1326 | Q16 | What Small molecule therapies have been approved by the FDA to treat mixed glioma? | There are no drug Small molecule therapies approved to treat mixed glioma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mixed glioma" OR LOWER(mesh_heading) = "mixed glioma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1154 | Q16 | What Small molecule therapies have been approved by the FDA to treat human papilloma virus infection? | There are no drug Small molecule therapies approved to treat human papilloma virus infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "human papilloma virus infection" OR LOWER(mesh_heading) = "human papilloma virus infection") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.142 | Q16 | What Protein therapies have been approved by the FDA to treat diabetes insipidus? | There are 2 Protein therapy drugs that are approved to treat diabetes insipidus which are as follows: Vasopressin and Desmopressin Acetate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "diabetes insipidus" OR LOWER(mesh_heading) = "diabetes insipidus") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_692517', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692535', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692553', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692571', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692589', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692607', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692625', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692643', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692661', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692679', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692697', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692715', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692733', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692751', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692769', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692787', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692805', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692823', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692841', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692859', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692877', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692895', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692913', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692931', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692949', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692967', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_692985', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693003', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693021', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693039', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693057', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693075', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693093', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693111', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693129', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693147', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693165', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693183', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693201', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693219', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693237', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693255', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693273', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693291', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693309', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693327', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693345', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693363', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693381', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693399', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693417', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693435', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693453', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693471', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693489', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693507', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693525', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693543', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693561', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693579', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693597', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693615', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693633', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693651', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693669', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693687', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693705', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693723', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693741', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693759', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693777', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693795', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693813', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693831', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693849', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693867', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693885', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693903', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693921', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693939', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693957', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693975', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_693993', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694011', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694029', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694047', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694065', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694083', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694101', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694119', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694137', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694155', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694173', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694191', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694209', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694227', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694245', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694263', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694281', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}, {'UUID': 'DrugTargetsIndication121923_text_694299', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.881 | Q16 | What Small molecule therapies have been approved by the FDA to treat cerebral astrocytoma? | There are no drug Small molecule therapies approved to treat cerebral astrocytoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cerebral astrocytoma" OR LOWER(mesh_heading) = "cerebral astrocytoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.593 | Q16 | What Small molecule therapies have been approved by the FDA to treat Plasmodium falciparum malaria? | There are no drug Small molecule therapies approved to treat Plasmodium falciparum malaria. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "plasmodium falciparum malaria" OR LOWER(mesh_heading) = "plasmodium falciparum malaria") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1645 | Q16 | What Small molecule therapies have been approved by the FDA to treat spinal fracture? | There are no drug Small molecule therapies approved to treat spinal fracture. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "spinal fracture" OR LOWER(mesh_heading) = "spinal fracture") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.342 | Q16 | What Small molecule therapies have been approved by the FDA to treat Aortic Coarctation? | There are no drug Small molecule therapies approved to treat Aortic Coarctation. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "aortic coarctation" OR LOWER(mesh_heading) = "aortic coarctation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.397 | Q16 | What Small molecule therapies have been approved by the FDA to treat Congenital myasthenic syndromes? | There are no drug Small molecule therapies approved to treat Congenital myasthenic syndromes. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "congenital myasthenic syndromes" OR LOWER(mesh_heading) = "congenital myasthenic syndromes") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.742 | Q16 | What Small molecule therapies have been approved by the FDA to treat alopecia areata? | There are no drug Small molecule therapies approved to treat alopecia areata. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "alopecia areata" OR LOWER(mesh_heading) = "alopecia areata") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.273 | Q16 | What Protein therapies have been approved by the FDA to treat prostate adenocarcinoma? | There are 4 Protein therapy drugs that are approved to treat prostate adenocarcinoma which are as follows: Leuprolide Acetate, Histrelin Acetate, Degarelix Acetate, and Triptorelin Pamoate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prostate adenocarcinoma" OR LOWER(mesh_heading) = "prostate adenocarcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097003', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097025', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097047', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097069', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097091', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097113', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097120', 'drugName': 'Histrelin Acetate', 'tradeNames_list': "['Supprelin', 'Supprelin la', 'Vantas']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097123', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097127', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097131', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097135', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097139', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097143', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097147', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097151', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097155', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097159', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097285', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097292', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.185 | Q16 | What Protein therapies have been approved by the FDA to treat intermediate uveitis? | There are no drug Protein therapies approved to treat intermediate uveitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intermediate uveitis" OR LOWER(mesh_heading) = "intermediate uveitis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.872 | Q16 | What Small molecule therapies have been approved by the FDA to treat carotid atherosclerosis? | There are no drug Small molecule therapies approved to treat carotid atherosclerosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "carotid atherosclerosis" OR LOWER(mesh_heading) = "carotid atherosclerosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.246 | Q16 | What Protein therapies have been approved by the FDA to treat osteoarthritis, knee? | There are no drug Protein therapies approved to treat osteoarthritis, knee. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "osteoarthritis, knee" OR LOWER(mesh_heading) = "osteoarthritis, knee") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.420 | Q16 | What Small molecule therapies have been approved by the FDA to treat Dysphagia? | There are no drug Small molecule therapies approved to treat Dysphagia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dysphagia" OR LOWER(mesh_heading) = "dysphagia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.586 | Q16 | What Small molecule therapies have been approved by the FDA to treat Patent foramen ovale? | There are no drug Small molecule therapies approved to treat Patent foramen ovale. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "patent foramen ovale" OR LOWER(mesh_heading) = "patent foramen ovale") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.305 | Q16 | What Protein therapies have been approved by the FDA to treat thrombotic disease? | Bivalirudin is the only Protein therapy approved by the FDA to treat thrombotic disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thrombotic disease" OR LOWER(mesh_heading) = "thrombotic disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092313', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092330', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092347', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092364', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.536 | Q16 | What Small molecule therapies have been approved by the FDA to treat Lymphoma, AIDS-Related? | There are no drug Small molecule therapies approved to treat Lymphoma, AIDS-Related. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lymphoma, aids-related" OR LOWER(mesh_heading) = "lymphoma, aids-related") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.875 | Q16 | What Small molecule therapies have been approved by the FDA to treat causalgia? | There are no drug Small molecule therapies approved to treat causalgia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "causalgia" OR LOWER(mesh_heading) = "causalgia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.873 | Q16 | What Small molecule therapies have been approved by the FDA to treat carpal tunnel syndrome? | There are no drug Small molecule therapies approved to treat carpal tunnel syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "carpal tunnel syndrome" OR LOWER(mesh_heading) = "carpal tunnel syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1664 | Q16 | What Small molecule therapies have been approved by the FDA to treat subacute thyroiditis? | There are 2 Small molecule therapy drugs that are approved to treat subacute thyroiditis which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "subacute thyroiditis" OR LOWER(mesh_heading) = "subacute thyroiditis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217672', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_217880', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_218088', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_218296', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_218504', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_218712', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_218920', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_219128', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_219336', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_219544', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_219752', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_219960', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_220168', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_220376', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_220584', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_220792', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_226369', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_226654', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_226939', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_227224', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_227509', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_227794', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_228079', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_228364', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_228649', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_228934', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_229219', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_229504', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_229789', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_230074', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_230359', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_230644', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_230929', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_231214', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_231499', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_231784', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_232069', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_232354', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1579 | Q16 | What Small molecule therapies have been approved by the FDA to treat retinal artery occlusion? | There are no drug Small molecule therapies approved to treat retinal artery occlusion. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "retinal artery occlusion" OR LOWER(mesh_heading) = "retinal artery occlusion") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.252 | Q16 | What Protein therapies have been approved by the FDA to treat panuveitis? | There are no drug Protein therapies approved to treat panuveitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "panuveitis" OR LOWER(mesh_heading) = "panuveitis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.457 | Q16 | What Small molecule therapies have been approved by the FDA to treat Glycogen storage disease due to acid maltase deficiency? | There are no drug Small molecule therapies approved to treat Glycogen storage disease due to acid maltase deficiency. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "glycogen storage disease due to acid maltase deficiency" OR LOWER(mesh_heading) = "glycogen storage disease due to acid maltase deficiency") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1455 | Q16 | What Small molecule therapies have been approved by the FDA to treat penile cancer? | There are no drug Small molecule therapies approved to treat penile cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "penile cancer" OR LOWER(mesh_heading) = "penile cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.561 | Q16 | What Small molecule therapies have been approved by the FDA to treat Nasal Cavity Polyp? | There are 2 Small molecule therapy drugs that are approved to treat Nasal Cavity Polyp which are as follows: Fluticasone Propionate and Mometasone Furoate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "nasal cavity polyp" OR LOWER(mesh_heading) = "nasal cavity polyp") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232400', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232427', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232454', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232481', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232508', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232535', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232562', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232589', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232616', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232643', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232670', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232697', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232724', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232751', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232778', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232805', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232832', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232859', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232886', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232913', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232940', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232967', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_232994', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233021', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233048', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233075', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233102', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233129', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233156', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233183', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233210', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233237', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233264', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233291', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233318', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233345', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233372', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233399', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233426', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233453', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233480', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233507', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233534', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233561', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233588', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233615', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233642', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233669', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233696', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233723', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233750', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233777', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233804', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233831', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233858', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233885', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233912', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233939', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233966', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_233993', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234020', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234047', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234074', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234101', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234128', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234155', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234182', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234209', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234236', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234263', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234290', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234317', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234344', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234371', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234398', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234425', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234452', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234479', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234506', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234533', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234560', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234587', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234614', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234641', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234668', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234695', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234722', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234749', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234776', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234803', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234830', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234857', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234884', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234911', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234938', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234965', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_234992', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_235019', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_235046', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}, {'UUID': 'DrugTargetsIndication121923_text_235073', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1710 | Q16 | What Small molecule therapies have been approved by the FDA to treat triple-negative breast cancer? | There are no drug Small molecule therapies approved to treat triple-negative breast cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "triple-negative breast cancer" OR LOWER(mesh_heading) = "triple-negative breast cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.501 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hyperinsulinemia? | There are no drug Small molecule therapies approved to treat Hyperinsulinemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hyperinsulinemia" OR LOWER(mesh_heading) = "hyperinsulinemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.594 | Q16 | What Small molecule therapies have been approved by the FDA to treat Pneumonia, Aspiration? | There are no drug Small molecule therapies approved to treat Pneumonia, Aspiration. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pneumonia, aspiration" OR LOWER(mesh_heading) = "pneumonia, aspiration") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1501 | Q16 | What Small molecule therapies have been approved by the FDA to treat post operative nausea and vomiting? | There are 7 Small molecule therapy drugs that are approved to treat post operative nausea and vomiting which are as follows: Amisulpride, Metoclopramide Hydrochloride, Palonosetron Hydrochloride, Granisetron, Ondansetron, Aprepitant, and Fosaprepitant Dimeglumine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "post operative nausea and vomiting" OR LOWER(mesh_heading) = "post operative nausea and vomiting") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_151447', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151460', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151473', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151486', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151499', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151512', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151525', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151538', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151551', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151564', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151577', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151590', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151603', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151616', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151629', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151642', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151655', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151668', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151681', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151694', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151707', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151720', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151733', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151746', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151759', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151772', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151785', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151798', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151811', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151824', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151837', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151850', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151863', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151876', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151889', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151902', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151915', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151928', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151941', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151954', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151967', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151980', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151993', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152006', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152019', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152032', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152045', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152058', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152071', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152084', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152097', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152110', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152123', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152136', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152149', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152162', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152175', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152188', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152201', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152214', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152227', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152240', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152253', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152266', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152279', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152292', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152305', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152318', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152331', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152344', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152357', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152370', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152383', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152396', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152409', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152422', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152435', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152448', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152461', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152474', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152487', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152500', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152513', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152526', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152539', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152552', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152565', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152578', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152591', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152604', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152617', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152630', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152643', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152656', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152669', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152682', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152695', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000186038', 'approvedSymbol': 'HTR3E', 'approvedName': '5-hydroxytryptamine receptor 3E', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152708', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000186038', 'approvedSymbol': 'HTR3E', 'approvedName': '5-hydroxytryptamine receptor 3E', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152721', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000186038', 'approvedSymbol': 'HTR3E', 'approvedName': '5-hydroxytryptamine receptor 3E', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152734', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000186038', 'approvedSymbol': 'HTR3E', 'approvedName': '5-hydroxytryptamine receptor 3E', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1677 | Q16 | What Small molecule therapies have been approved by the FDA to treat systemic lupus erythematosus? | There are 2 Small molecule therapy drugs that are approved to treat systemic lupus erythematosus which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "systemic lupus erythematosus" OR LOWER(mesh_heading) = "systemic lupus erythematosus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217637', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_217845', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_218053', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_218261', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_218469', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_218677', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_218885', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_219093', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_219301', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_219509', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_219717', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_219925', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_220133', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_220341', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_220549', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_220757', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_226331', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_226616', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_226901', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_227186', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_227471', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_227756', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_228041', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_228326', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_228611', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_228896', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_229181', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_229466', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_229751', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_230036', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_230321', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_230606', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_230891', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_231176', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_231461', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_231746', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_232031', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}, {'UUID': 'DrugTargetsIndication121923_text_232316', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1673 | Q16 | What Small molecule therapies have been approved by the FDA to treat syndromic disease? | There are no drug Small molecule therapies approved to treat syndromic disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "syndromic disease" OR LOWER(mesh_heading) = "syndromic disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.826 | Q16 | What Small molecule therapies have been approved by the FDA to treat bladder tumor? | Erdafitinib is the only Small molecule therapy approved by the FDA to treat bladder tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bladder tumor" OR LOWER(mesh_heading) = "bladder tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_707092', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707108', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707124', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707140', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707156', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707172', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707188', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707204', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707220', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707236', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707252', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707268', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707284', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707300', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707316', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707332', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707348', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707364', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707380', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707396', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707412', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707428', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707444', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707460', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707476', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707492', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707508', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707524', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707540', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707556', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707572', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707588', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707604', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707620', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707636', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707652', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707668', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707684', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707700', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707716', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707732', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707748', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707764', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707780', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707796', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707812', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707828', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707844', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707860', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707876', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707892', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707908', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707924', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707940', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707956', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707972', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_707988', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708004', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708020', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708036', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708052', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708068', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708084', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708100', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708116', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708132', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708148', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708164', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708180', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708196', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708212', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708228', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708244', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708260', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708276', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708292', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708308', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708324', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708340', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708356', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708372', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708388', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708404', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708420', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708436', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708452', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708468', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708484', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708500', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708516', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708532', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708548', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708564', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708580', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708596', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}, {'UUID': 'DrugTargetsIndication121923_text_708612', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.960 | Q16 | What Small molecule therapies have been approved by the FDA to treat coronary artery disease? | There are 8 Small molecule therapy drugs that are approved to treat coronary artery disease which are as follows: Aspirin, Ticagrelor, Nitroglycerin, Amlodipine Besylate, Amlodipine Benzoate, Simvastatin, Rosuvastatin Calcium, and Bempedoic Acid. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "coronary artery disease" OR LOWER(mesh_heading) = "coronary artery disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833648', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_833805', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_833962', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_834119', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_834276', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_834433', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_834590', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_834747', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_834904', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_835061', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_835218', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_835375', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_835532', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_835689', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_835846', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_836003', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920337', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920363', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920389', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920415', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920441', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920467', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920493', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920519', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920545', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920571', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920597', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920623', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920649', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920675', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920701', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920727', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920753', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920779', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920805', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920831', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920857', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920883', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920909', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920935', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920961', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_920987', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_937023', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_937046', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_937069', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_937092', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_972478', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_972512', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_972546', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_972580', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_972614', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000152402', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_972648', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000152402', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_972682', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000164116', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_972716', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000164116', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043667', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043681', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043695', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043709', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043723', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043737', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043751', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043765', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043779', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043793', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043807', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043821', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043835', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043849', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043863', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043877', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043891', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043905', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043919', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043933', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043947', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043961', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043975', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043989', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1043999', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044005', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044011', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044017', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044023', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044029', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044035', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044041', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044047', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044053', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044059', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044065', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044071', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044077', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044083', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044089', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044095', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044101', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044107', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044113', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044119', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}, {'UUID': 'DrugTargetsIndication121923_text_1044125', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.171 | Q16 | What Protein therapies have been approved by the FDA to treat hepatitis C virus infection? | There are no drug Protein therapies approved to treat hepatitis C virus infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hepatitis c virus infection" OR LOWER(mesh_heading) = "hepatitis c virus infection") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1609 | Q16 | What Small molecule therapies have been approved by the FDA to treat seborrheic dermatitis? | There are 4 Small molecule therapy drugs that are approved to treat seborrheic dermatitis which are as follows: Prednisone, Dexamethasone, Fluocinolone Acetonide, and Hydrocortisone Butyrate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "seborrheic dermatitis" OR LOWER(mesh_heading) = "seborrheic dermatitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217667', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_217875', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218083', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218291', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218499', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218707', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218915', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219123', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219331', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219539', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219747', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219955', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_220163', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_220371', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_220579', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_220787', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_226363', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_226648', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_226933', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_227218', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_227503', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_227788', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_228073', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_228358', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_228643', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_228928', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_229213', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_229498', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_229783', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_230068', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_230353', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_230638', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_230923', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_231208', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_231493', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_231778', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_232063', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_232348', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_242240', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_242256', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_243803', 'drugName': 'Hydrocortisone Butyrate', 'tradeNames_list': "['Hydrocortisone butyrate', 'Locoid', 'Locoid c', 'Locoid creloLocoid lipocream']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_243807', 'drugName': 'Hydrocortisone Butyrate', 'tradeNames_list': "['Hydrocortisone butyrate', 'Locoid', 'Locoid c', 'Locoid creloLocoid lipocream']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.377 | Q16 | What Small molecule therapies have been approved by the FDA to treat Canavan disease? | There are no drug Small molecule therapies approved to treat Canavan disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "canavan disease" OR LOWER(mesh_heading) = "canavan disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.624 | Q16 | What Small molecule therapies have been approved by the FDA to treat Shwachman-Diamond syndrome? | There are no drug Small molecule therapies approved to treat Shwachman-Diamond syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "shwachman-diamond syndrome" OR LOWER(mesh_heading) = "shwachman-diamond syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.302 | Q16 | What Protein therapies have been approved by the FDA to treat syndromic disease? | Bivalirudin is the only Protein therapy approved by the FDA to treat syndromic disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "syndromic disease" OR LOWER(mesh_heading) = "syndromic disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092314', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Syndrome', 'efo_term': 'syndromic disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092331', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Syndrome', 'efo_term': 'syndromic disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092348', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Syndrome', 'efo_term': 'syndromic disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092365', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Syndrome', 'efo_term': 'syndromic disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1651 | Q16 | What Small molecule therapies have been approved by the FDA to treat spondyloarthropathy? | There are no drug Small molecule therapies approved to treat spondyloarthropathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "spondyloarthropathy" OR LOWER(mesh_heading) = "spondyloarthropathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1099 | Q16 | What Small molecule therapies have been approved by the FDA to treat gastroenteritis? | There are no drug Small molecule therapies approved to treat gastroenteritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gastroenteritis" OR LOWER(mesh_heading) = "gastroenteritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1474 | Q16 | What Small molecule therapies have been approved by the FDA to treat pharynx cancer? | There are no drug Small molecule therapies approved to treat pharynx cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pharynx cancer" OR LOWER(mesh_heading) = "pharynx cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1100 | Q16 | What Small molecule therapies have been approved by the FDA to treat gastroesophageal reflux disease? | There are 7 Small molecule therapy drugs that are approved to treat gastroesophageal reflux disease which are as follows: Pantoprazole Sodium, Esomeprazole Magnesium, Omeprazole, Lansoprazole, Dexlansoprazole, Nizatidine, and Famotidine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gastroesophageal reflux disease" OR LOWER(mesh_heading) = "gastroesophageal reflux disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097747', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097752', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097757', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097762', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097767', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097772', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097777', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097782', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097787', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097792', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097797', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097802', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097807', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097812', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097817', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097822', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097827', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097832', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097837', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097842', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097847', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097852', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097861', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097873', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097885', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097897', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097967', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098037', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098107', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098177', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098247', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098317', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098344', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098368', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098392', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098416', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098423', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098431', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098439', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098447', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098455', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098463', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098471', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098479', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098487', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098495', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098503', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098511', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098519', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098527', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098535', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098543', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098551', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098559', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098567', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098575', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098583', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098591', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098599', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098607', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098615', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098623', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098631', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098639', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098647', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098655', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098663', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098671', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098679', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098687', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098695', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098703', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098711', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098719', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098727', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098735', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098743', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098751', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098759', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098767', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098775', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098783', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098791', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098799', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098807', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098815', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098823', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098831', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098839', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098847', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098855', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098863', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098871', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098879', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098887', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098895', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098903', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098911', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098919', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098927', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.485 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hereditary breast and ovarian cancer syndrome? | There are no drug Small molecule therapies approved to treat Hereditary breast and ovarian cancer syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hereditary breast and ovarian cancer syndrome" OR LOWER(mesh_heading) = "hereditary breast and ovarian cancer syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1726 | Q16 | What Small molecule therapies have been approved by the FDA to treat urethra cancer? | There are no drug Small molecule therapies approved to treat urethra cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "urethra cancer" OR LOWER(mesh_heading) = "urethra cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1008 | Q16 | What Small molecule therapies have been approved by the FDA to treat duodenal ulcer? | There are 5 Small molecule therapy drugs that are approved to treat duodenal ulcer which are as follows: Esomeprazole Magnesium, Omeprazole, Dexlansoprazole, Nizatidine, and Famotidine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "duodenal ulcer" OR LOWER(mesh_heading) = "duodenal ulcer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097862', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1097874', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1097886', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1097898', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1097968', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098038', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098108', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098178', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098248', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098318', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098424', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098432', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098440', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098448', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098456', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098464', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098472', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098480', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098488', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098496', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098504', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098512', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098520', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098528', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098536', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098544', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098552', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098560', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098568', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098576', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098584', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098592', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098600', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098608', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098616', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098624', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098632', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098640', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098648', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098656', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098664', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098672', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098680', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098688', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098696', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098704', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098712', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098720', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098728', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098736', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098744', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098752', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098760', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098768', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098776', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098784', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098792', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098800', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098808', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098816', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098824', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098832', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098840', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098848', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098856', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098864', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098872', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098880', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098888', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098896', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098904', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098912', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098920', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098928', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098936', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098944', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098952', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098960', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098968', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098976', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098984', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098992', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099000', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099008', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099016', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099024', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099032', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099040', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099048', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099056', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099064', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099072', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099080', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099088', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099096', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099104', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099112', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099120', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099128', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1099136', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1718 | Q16 | What Small molecule therapies have been approved by the FDA to treat ulcer disease? | Famotidine is the only Small molecule therapy approved by the FDA to treat ulcer disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ulcer disease" OR LOWER(mesh_heading) = "ulcer disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100340', 'drugName': 'Famotidine', 'tradeNames_list': "['Famotidine', 'Famotidine preservative freeFamotidine preservative free (pharmacy bulk)', 'Fluxid', 'PepcidPepcid ac', 'Pepcid preservative free', 'Pepcid rpd']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000113749', 'approvedSymbol': 'HRH2', 'approvedName': 'histamine receptor H2', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ulcer', 'efo_term': 'ulcer disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.518 | Q16 | What Small molecule therapies have been approved by the FDA to treat Iridocyclitis? | There are 2 Small molecule therapy drugs that are approved to treat Iridocyclitis which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "iridocyclitis" OR LOWER(mesh_heading) = "iridocyclitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217622', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_217830', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_218038', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_218246', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_218454', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_218662', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_218870', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_219078', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_219286', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_219494', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_219702', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_219910', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_220118', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_220326', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_220534', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_220742', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_226312', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_226597', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_226882', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_227167', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_227452', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_227737', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_228022', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_228307', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_228592', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_228877', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_229162', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_229447', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_229732', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_230017', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_230302', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_230587', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_230872', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_231157', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_231442', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_231727', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_232012', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}, {'UUID': 'DrugTargetsIndication121923_text_232297', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.353 | Q16 | What Small molecule therapies have been approved by the FDA to treat Autosomal dominant polycystic kidney disease? | There are no drug Small molecule therapies approved to treat Autosomal dominant polycystic kidney disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "autosomal dominant polycystic kidney disease" OR LOWER(mesh_heading) = "autosomal dominant polycystic kidney disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.828 | Q16 | What Small molecule therapies have been approved by the FDA to treat blood coagulation disease? | There are no drug Small molecule therapies approved to treat blood coagulation disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "blood coagulation disease" OR LOWER(mesh_heading) = "blood coagulation disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1094 | Q16 | What Small molecule therapies have been approved by the FDA to treat gastric cancer? | There are no drug Small molecule therapies approved to treat gastric cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gastric cancer" OR LOWER(mesh_heading) = "gastric cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.176 | Q16 | What Protein therapies have been approved by the FDA to treat hyperlipidemia? | There are no drug Protein therapies approved to treat hyperlipidemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hyperlipidemia" OR LOWER(mesh_heading) = "hyperlipidemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.615 | Q16 | What Small molecule therapies have been approved by the FDA to treat Rett syndrome? | There are no drug Small molecule therapies approved to treat Rett syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "rett syndrome" OR LOWER(mesh_heading) = "rett syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.944 | Q16 | What Small molecule therapies have been approved by the FDA to treat colorectal cancer? | Regorafenib is the only Small molecule therapy approved by the FDA to treat colorectal cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "colorectal cancer" OR LOWER(mesh_heading) = "colorectal cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_664067', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664103', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664139', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664175', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664211', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664247', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664283', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664319', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664355', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664391', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664427', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664463', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664499', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664535', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664571', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664607', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664643', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664679', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664715', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664751', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664787', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664823', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664859', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664895', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664931', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_664967', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665003', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665039', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665075', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665111', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665147', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665183', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665219', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665255', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665291', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665327', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665363', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665399', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665435', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665471', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665507', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665543', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665579', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665615', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665651', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665687', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665723', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665759', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665795', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665831', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665867', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665903', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665939', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_665975', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666011', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666047', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666083', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666119', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666155', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666191', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666227', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666263', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666299', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666335', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666371', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666407', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666443', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666479', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666515', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666551', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666587', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666623', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666659', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666695', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666731', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666767', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666803', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666839', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666875', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666911', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666947', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_666983', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_667019', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_667055', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_667091', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_667127', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_667163', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_667199', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_667235', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}, {'UUID': 'DrugTargetsIndication121923_text_667271', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.995 | Q16 | What Small molecule therapies have been approved by the FDA to treat diffuse large B-cell lymphoma? | There are 2 Small molecule therapy drugs that are approved to treat diffuse large B-cell lymphoma which are as follows: Crizotinib and Selinexor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "diffuse large b-cell lymphoma" OR LOWER(mesh_heading) = "diffuse large b-cell lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_934288', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934310', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934332', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934354', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934376', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934398', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934420', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934442', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934464', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934486', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934508', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934530', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934552', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934574', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934596', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934618', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934640', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934662', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934684', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934706', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934728', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934750', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934772', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934794', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934816', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934838', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934860', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934882', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934904', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934926', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934948', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934970', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_934992', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935014', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935036', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935058', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935080', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935102', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935124', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935146', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935168', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935190', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935212', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935234', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935256', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935278', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935300', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935322', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935344', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935366', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935388', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935410', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935432', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935454', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935476', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935498', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935520', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935542', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935564', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935586', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935608', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935630', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935652', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935674', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935696', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935718', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935740', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935762', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935784', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935806', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935828', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935850', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935872', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935894', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935916', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935938', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935960', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_935982', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_936004', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_936026', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_936048', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_936070', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_936092', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_936114', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000181163', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1193718', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1193760', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1193802', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1193844', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1193886', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1193928', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1193970', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1194012', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1194054', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1194096', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1194138', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1194180', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1194222', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1194264', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1194306', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1194348', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000082898', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.894 | Q16 | What Small molecule therapies have been approved by the FDA to treat childhood acute lymphoblastic leukemia? | There are 2 Small molecule therapy drugs that are approved to treat childhood acute lymphoblastic leukemia which are as follows: Dasatinib and Methotrexate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "childhood acute lymphoblastic leukemia" OR LOWER(mesh_heading) = "childhood acute lymphoblastic leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_713211', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713289', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713367', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713445', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713523', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713601', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713679', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713757', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713835', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713913', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_713991', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714069', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714147', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714225', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714303', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714381', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714459', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714537', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714615', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714693', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714771', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714849', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_714927', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715005', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715083', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715161', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715239', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715317', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715395', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715473', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715551', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715629', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715707', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715785', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715863', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_715941', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716019', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716097', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716175', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716253', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716331', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716409', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716487', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716565', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716643', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716721', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716799', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716877', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_716955', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717033', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717111', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717189', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717267', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717345', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717423', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717501', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717579', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717657', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717735', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717813', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717891', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_717969', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718047', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718125', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718203', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718281', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718359', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718437', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718515', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718593', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718671', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718749', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718827', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718905', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_718983', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719061', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719139', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719217', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719295', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719373', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719451', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719529', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719607', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719685', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719763', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719841', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719919', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_719997', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720075', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720153', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720231', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720309', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720387', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720465', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720543', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720621', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720699', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720777', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720855', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_720933', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1647 | Q16 | What Small molecule therapies have been approved by the FDA to treat spinal stenosis? | There are no drug Small molecule therapies approved to treat spinal stenosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "spinal stenosis" OR LOWER(mesh_heading) = "spinal stenosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1630 | Q16 | What Small molecule therapies have been approved by the FDA to treat skin carcinoma? | There are no drug Small molecule therapies approved to treat skin carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "skin carcinoma" OR LOWER(mesh_heading) = "skin carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.933 | Q16 | What Small molecule therapies have been approved by the FDA to treat clear cell sarcoma? | There are no drug Small molecule therapies approved to treat clear cell sarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "clear cell sarcoma" OR LOWER(mesh_heading) = "clear cell sarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.199 | Q16 | What Protein therapies have been approved by the FDA to treat leprosy? | There are no drug Protein therapies approved to treat leprosy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "leprosy" OR LOWER(mesh_heading) = "leprosy") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.16 | Q16 | What Protein therapies have been approved by the FDA to treat ACTH Syndrome, Ectopic? | There are no drug Protein therapies approved to treat ACTH Syndrome, Ectopic. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acth syndrome, ectopic" OR LOWER(mesh_heading) = "acth syndrome, ectopic") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.267 | Q16 | What Protein therapies have been approved by the FDA to treat precocious puberty? | There are 2 Protein therapy drugs that are approved to treat precocious puberty which are as follows: Leuprolide Acetate and Triptorelin Pamoate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "precocious puberty" OR LOWER(mesh_heading) = "precocious puberty") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097006', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097028', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097050', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097072', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097094', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097116', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097288', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097295', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'precocious puberty'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.533 | Q16 | What Small molecule therapies have been approved by the FDA to treat Lennox-Gastaut syndrome? | There are 5 Small molecule therapy drugs that are approved to treat Lennox-Gastaut syndrome which are as follows: Topiramate, Rufinamide, Lamotrigine, Clobazam, and Cannabidiol. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lennox-gastaut syndrome" OR LOWER(mesh_heading) = "lennox-gastaut syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_457240', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457285', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457330', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457375', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457420', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457465', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457510', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457555', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457600', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457645', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457690', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457735', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457780', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457825', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457870', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457915', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_457960', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458005', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458050', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458095', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458140', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458185', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458230', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458275', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458320', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458365', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458410', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458455', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458500', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458545', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458590', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458635', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458680', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458725', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458770', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458815', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458860', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458905', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458950', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_458995', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459040', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459085', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459130', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459175', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459220', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459265', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459310', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459355', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459400', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459445', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459490', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459535', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459580', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459625', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459670', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459715', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459760', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459805', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459850', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459895', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459940', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_459985', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460030', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460075', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460120', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460165', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460210', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460255', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460300', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460345', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460390', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460435', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460480', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460525', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460570', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460615', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460660', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460705', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460750', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460795', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460840', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460885', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460930', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_460975', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461020', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461065', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461110', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461155', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461200', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461245', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461290', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461335', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461380', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461425', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461470', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461515', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461560', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461605', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461650', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_461695', 'drugName': 'Topiramate', 'tradeNames_list': "['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkleTopiramate', 'Trokendi xr']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1496 | Q16 | What Small molecule therapies have been approved by the FDA to treat polymyositis? | Prednisone is the only Small molecule therapy approved by the FDA to treat polymyositis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "polymyositis" OR LOWER(mesh_heading) = "polymyositis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217638', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_217846', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218054', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218262', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218470', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218678', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218886', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219094', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219302', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219510', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219718', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219926', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_220134', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_220342', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_220550', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}, {'UUID': 'DrugTargetsIndication121923_text_220758', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.788 | Q16 | What Small molecule therapies have been approved by the FDA to treat arthritis? | There are 8 Small molecule therapy drugs that are approved to treat arthritis which are as follows: Prednisone, Lidocaine, Acetaminophen, Aspirin, Naproxen, Ibuprofen, Capsaicin, and Methotrexate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "arthritis" OR LOWER(mesh_heading) = "arthritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217650', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_217858', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218066', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218274', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218482', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218690', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_218898', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219106', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219314', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219522', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219730', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_219938', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_220146', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_220354', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_220562', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_220770', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_637787', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_637902', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_638017', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_638132', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_638247', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_638362', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_638477', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_638592', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_638707', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_638822', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_638937', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_639052', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_639167', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_639282', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_639397', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_639512', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_639627', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_639742', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_639857', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_639972', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_640087', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_640202', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_640317', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_640432', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_640547', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_640662', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_640777', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_640892', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_641007', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_641122', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_641237', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_641352', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_641467', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_641582', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_641697', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_641812', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_641927', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_642042', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_642157', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_642272', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_642387', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_642502', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_642617', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_642732', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_642847', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_642962', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_643077', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_643192', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_643307', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_643422', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_643537', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_643652', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_643767', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_643882', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_643997', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_644112', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_644227', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_644342', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_644457', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_644572', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_828737', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_828842', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_828947', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_829052', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_829157', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_829262', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_829367', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_829472', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_829577', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_829682', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_829787', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_829892', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_829997', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_830102', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_830207', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_830312', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_830417', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_830522', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_830627', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_830732', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_830837', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_830942', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_831047', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_831152', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1364 | Q16 | What Small molecule therapies have been approved by the FDA to treat neoplasm of mature B-cells? | There are 3 Small molecule therapy drugs that are approved to treat neoplasm of mature B-cells which are as follows: Copanlisib Hydrochloride, Idelalisib, and Duvelisib. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neoplasm of mature b-cells" OR LOWER(mesh_heading) = "neoplasm of mature b-cells") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_858315', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858324', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858333', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858342', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858351', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000121879', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858360', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000121879', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858369', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000121879', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858378', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000121879', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858395', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858414', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858433', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858452', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858471', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858490', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858509', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858528', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858547', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858566', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858585', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858604', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858623', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858642', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858661', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858680', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858699', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858718', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858736', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858756', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858776', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858796', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858816', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858836', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858856', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858876', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858896', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858916', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858936', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858956', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858976', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_858996', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859016', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859036', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859056', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859076', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859096', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859116', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859136', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859156', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859176', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859196', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859216', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859236', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859256', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}, {'UUID': 'DrugTargetsIndication121923_text_859276', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.